In the latest session, Clearside Biomedical Inc (NASDAQ: CLSD) closed at $1.64 down -18.81% from its previous closing price of $2.02. In other words, the price has decreased by -$0.3800 from its previous closing price. On the day, 1111765 shares were traded. CLSD stock price reached its highest trading level at $2.1200 during the session, while it also had its lowest trading level at $1.5800.
Ratios:
For a deeper understanding of Clearside Biomedical Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.28 and its Current Ratio is at 5.28.
On July 29, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
On May 13, 2020, ROTH Capital started tracking the stock assigning a Buy rating and target price of $8.ROTH Capital initiated its Buy rating on May 13, 2020, with a $8 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 07 ’24 when WHITMORE BRADFORD T bought 444,444 shares for $1.35 per share. The transaction valued at 599,999 led to the insider holds 4,495,034 shares of the business.
LASEZKAY GEORGE M sold 18,000 shares of CLSD for $22,860 on Jan 19 ’24. The CEO now owns 466,577 shares after completing the transaction at $1.27 per share. On Jan 19 ’24, another insider, Deignan Charles A., who serves as the Chief Financial Officer of the company, sold 12,900 shares for $1.28 each. As a result, the insider received 16,512 and left with 384,662 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLSD now has a Market Capitalization of 122.54M and an Enterprise Value of 94.83M. For the stock, the TTM Price-to-Sale (P/S) ratio is 55.45. Its current Enterprise Value per Revenue stands at 42.89 whereas that against EBITDA is -3.37.
Stock Price History:
Over the past 52 weeks, CLSD has reached a high of $2.07, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is 1.3759, while the 200-Day Moving Average is calculated to be 1.1091.
Shares Statistics:
For the past three months, CLSD has traded an average of 293.52K shares per day and 859.58k over the past ten days. A total of 74.72M shares are outstanding, with a floating share count of 63.03M. Insiders hold about 15.65% of the company’s shares, while institutions hold 13.32% stake in the company. Shares short for CLSD as of Feb 29, 2024 were 275.4k with a Short Ratio of 0.94, compared to 183.92k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.37% and a Short% of Float of 0.39%.
Earnings Estimates
There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.05 and a low estimate of -$0.15, while EPS last year was -$0.16. The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.12 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.5 and -$0.6 for the fiscal current year, implying an average EPS of -$0.53. EPS for the following year is -$0.58, with 6 analysts recommending between -$0.53 and -$0.65.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $4.43M this quarter.It ranges from a high estimate of $6M to a low estimate of $200k. As of the current estimate, Clearside Biomedical Inc’s year-ago sales were $330k, an estimated increase of 1,242.40% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for CLSD’s current fiscal year. The highest revenue estimate was $7.9M, while the lowest revenue estimate was $2.08M, resulting in an average revenue estimate of $6.32M. In the same quarter a year ago, actual revenue was $1.33M, up 376.30% from the average estimate.
